Investor Relations

Contact Information

For Investor inquiries call
+1 908-298-7436


For Investors

The information on this website is intended only for investors. All visitors should read our important advisory information


Notice to Holders of 6% Mandatory Convertible Preferred Stock of Schering-Plough Corporation


SP-Merck 146x132

Stock Quote

SGP (Common Stock)
ExchangeNYSE (US Dollar)
Price$36.46
Change (%) Stock is Up 1.13 (3.20%)
Volume36,364,804
As of 11/20/09 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Receive E-mail Alerts

Alerts are e-mailed whenever certain new company information is posted.

Sign-up Now!

Financial Tear Sheet

Say-on-Pay Survey


SEC Filings

Investor Toolkit:

Form 10-Q
MERCK & CO. INC. filed this Form 10-Q on Oct. 29, 2009
Document Outline
Entire Document (1.74 MB)
Subdocument 1 - 10-Q - FORM 10-Q
Page 1 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Page 2 - TABLE OF CONTENTS
Page 3 - SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 27 - EXECUTIVE OVERVIEW
Page 28 - Results and Highlights for the three and nine months ended September 30, 2009:
Page 29 - Cholesterol Franchise
Page 30 - Manufacturing, Sales and Marketing
Page 31 - N/A
Page 32 - N/A
Page 33 - Costs, Expenses and Equity Income
Page 34 - Selling, general and administrative
Page 35 - Equity income
Page 36 - LIQUIDITY AND FINANCIAL RESOURCES
Page 37 - REGULATORY AND COMPETITIVE ENVIRONMENT IN WHICH SCHERING-PLOUGH OPERATES
Page 38 - Regulatory Compliance and Pharmacovigilance
Page 39 - Regulatory Reform
Page 40 - Competition
Page 41 - DISCLOSURE NOTICE
Page 42 - N/A
Page 43 - PART II. OTHER INFORMATION
Page 44 - Patent Matters
Page 45 - Legal Proceedings Related to the Merck Combination
Page 46 - Key Schering-Plough products generate a significant amount of Schering-Plough s profits and cash flo
Page 47 - Patent disputes can be costly to prosecute and defend and adverse judgments could result in damage a
Page 48 - Market forces continue to evolve and can impact Schering-Plough s ability to sell products or the pr
Page 49 - There are other legal matters in which adverse outcomes could negatively affect Schering-Plough s re
Page 50 - Developments following regulatory approval may adversely affect sales of Schering-Plough s products.
Page 51 - Schering-Plough relies on third-party relationships for its key products, and the conduct and changi
Page 52 - Biologics carry unique risks and uncertainties, which could have a negative impact on future results
Page 53 - The current stock market and credit market conditions are extremely volatile and unpredictable. It i
Page 54 - N/A
Page 55 - N/A
Page 56 - SIGNATURES
Subdocument 2 - EX-12
Page 1 - Exhibit 12
Subdocument 3 - EX-15
Page 1 - Exhibit 15
Subdocument 4 - EX-31.1
Page 1 - Exhibit 31.1
Subdocument 5 - EX-31.2
Page 1 - Exhibit 31.2
Subdocument 6 - EX-32.1
Page 1 - Exhibit 32.1
Subdocument 7 - EX-32.2
Page 1 - Exhibit 32.2
XBRL Item - EX-101.INS - EX-101 INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - EX-101 SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - EX-101 CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - EX-101 LABELS LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - EX-101 PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - EX (What's this?)
XBRL Viewer